Anti-Human CD28 Reference Antibody (Theralizumab, RUO) (HY422026)

Name: Anti-Human CD28 Reference Antibody (Theralizumab, RUO)
Brand: abinScience
SKU: HY422026
Price: 320 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HY422026
Description	Theralizumab (HY422026) is a research-grade recombinant antibody targeting CD28. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG4
Système d'expression	Mammalian cells
Cible	CD28, TP44, T-cell-specific surface glycoprotein CD28
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P10747
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	TGN1412, TAB08, TAB-08, CD28-SuperMAB, 906068-56-2
Contexte	T-cell-specific surface glycoprotein CD28 is a ~25 kDa protein. Receptor that plays a role in T-cell activation, proliferation, survival and the maintenance of immune homeostasis. Functions not only as an amplifier of TCR signals but delivers unique signals that control intracellular biochemical events that alter the gene expression program of T-cells. Stimulation upon engagement of its cognate ligands CD80 or CD86 increases proliferation and expression of various cytokines in particular IL2 production in both CD4(+) and CD8(+) T-cell subsets. Mechanistically, ligation induces recruitment of protein kinase C-theta/PRKCQ and GRB2 leading to NF-kappa-B activation via both PI3K/Akt-dependent and -independent pathways. In conjunction with TCR/CD3 ligation and CD40L costimulation, enhances the production of IL4 and IL10 in T-cells. 1. Gimmi, CD. et al. (1991) Proceedings of the National Academy of Sciences of the United States of America 88, 6575-9. PMID: 1650475 2. Raab, M. et al. (1995) Proceedings of the National Academy of Sciences of the United States of America 92, 8891-5. PMID: 7568038 3. Skånland, SS. et al. (2014) The Biochemical journal 460, 399-410. PMID: 24665965 4. Collins, AV. et al. (2002) Immunity 17, 201-10. PMID: 12196291 5. Wu, H. et al. (2022) Structure (London, England : 1993) 30, 803-812.e5. PMID: 35397202 6. Kong, KF. et al. (2011) Nature immunology 12, 1105-12. PMID: 21964608 7. Blotta, MH. et al. (1996) Journal of immunology (Baltimore, Md. : 1950) 156, 3133-40. PMID: 8617933
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG4 (S228P) Recombinant Isotype Control Antibody (SAA0184) (HP298107)